Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - Deferred ChargesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInvestment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Abivax (ABVX) Research & Development: 2021-2024

Historic Research & Development for Abivax (ABVX) over the last 4 years, with Dec 2024 value amounting to $156.6 million.

  • Abivax's Research & Development fell 40.52% to -$43.7 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$116.2 million, marking a year-over-year decrease of 66.11%. This contributed to the annual value of $156.6 million for FY2024, which is 41.05% up from last year.
  • Abivax's Research & Development amounted to $156.6 million in FY2024, which was up 41.05% from $111.0 million recorded in FY2023.
  • In the past 5 years, Abivax's Research & Development registered a high of $156.6 million during FY2024, and its lowest value of $50.9 million during FY2022.
  • For the 3-year period, Abivax's Research & Development averaged around $106.2 million, with its median value being $111.0 million (2023).
  • Per our database at Business Quant, Abivax's Research & Development declined by 9.98% in 2022 and then surged by 118.09% in 2023.
  • Abivax's Research & Development (Yearly) stood at $56.5 million in 2021, then dropped by 9.98% to $50.9 million in 2022, then spiked by 118.09% to $111.0 million in 2023, then soared by 41.05% to $156.6 million in 2024.